Search clinical trials for: VRC-HIVADV014-00-VP

Total 169 results

National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase 1 Safety Study of Two Experimental HIV Vaccines

HIV Infections | HIV-1 | AIDS Vaccines

United States
National Institute of Allergy and Infectious Diseases...
Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaborators

Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

HIV Infections | Healthy

United States
National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

HIV Infections

Rwanda, Kenya
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

Innate Immunity | HIV Negative | Adaptive Immunity

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
International AIDS Vaccine Initiative

Withdrawn

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers

HIV Infections | Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine Treatment for HIV-Infection

Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

HIV Infections

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

HIV Infections

United States, Brazil, Haiti, Jamaica, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Healthy Adult Immune Responses to Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (DNA)

RNA Virus Infections | Virus Diseases | Flavivirus Infections | Flaviviridae Infections | Zika Virus Infection | Zika Virus | Flaviviral Diseases

United States, Puerto Rico, Mexico, Brazil, Colombia, Costa Rica, Ecuador, Panama, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Chikungunya Virus Infection

Dominican Republic, Puerto Rico, Guadeloupe, Haiti, Martinique
National Institute of Allergy and Infectious Diseases...

Completed

Ebola and Marburg Virus Vaccines

Ebola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | Ebolavirus

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Terminated

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC; US Military HIV Research Program

Completed

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Hemorrhagic Fever, Ebola

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

Healthy Adult Immune Responses to Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Ebola Vaccine Trial

Healthy | Hemorrhagic Fever, Ebola

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

Influenza A Virus, H1N1 Subtype | Novel Swine-Origin

United States
National Institute of Allergy and Infectious Diseases...

Completed

Candidate HIV Vaccine

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of West Nile Virus Vaccine

West Nile Fever

United States
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine to Prevent West Nile Virus Disease

Healthy | Healthy Volunteer | West Nile Fever | HV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

Prevention of Zika Infection | Zika-Specific Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Vaccine for Prevention of Ebola Virus Infection

Ebola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | Filovirus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

Prevention of Zika Infection | Zika-Specific Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1 Vaccine Test in Uninfected Adult Volunteers

HIV Seronegativity | AIDS Vaccines

United States
National Institute of Allergy and Infectious Diseases...

Completed

Chikungunya Virus Vaccine Trial in Healthy Adults

Chikungunya Fever | Chikungunya Virus Infection | Viral Vaccines

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Trial of Measles Vectored Chikungungya Vaccine

Chikungunya Virus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Influenza Infection

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Influenza

United States

Search clinical trials for: VRC-HIVADV014-00-VP

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations